Legal geographies of medication abortion in the USA
Legal geographies of medication abortion in the USA
复制标题
DOI：
10.1111/tran.12506
复制
发表时间：
2021-11-09
影响因子：
3.3
通讯作者：
Calkin, Sydney
中科院分区：
文献类型：
--
作者：
Calkin, Sydney
药物流产（米非司酮和米索前列醇）挑战了流产服务的空间性，因为它为在临床基础设施之外安全、自我管理流产创造了可能性。自从药物堕胎存在以来，支持堕胎和反对堕胎的人士就一直对这种可能性提出质疑。在本文中，我提供了药物流产技术的法律地理学解释，探讨了美国如何监管药物流产。从概念上讲，本文使用法律地理学方法来探讨堕胎法构建的社会空间。根据经验，本文分析了限制药物堕胎的立法趋势以及堕胎提供者针对药物堕胎限制提起诉讼的两个重大法庭挑战。根据米非司酮的立法和诉讼，我证明了对其的限制是通过将米非司酮固定在为手术流产建立的临床空间和监管框架内而发挥作用的。通过这种方式，米非司酮法规限制了其可用性，以防止创建可能重新安排其地理位置并扩大堕胎机会的替代堕胎模式。
Medication abortion with pills (mifepristone and misoprostol) challenges the spatiality of abortion provision because it creates the possibility for safe, self-managed abortion outside of clinical infrastructure. This possibility has been contested by pro- and anti-abortion actors for as long as medication abortion has been in existence. In this paper, I offer a legal geography account of medication abortion technology that examines how medication abortion has been regulated in the United States. Conceptually, the paper uses a legal geography methodology to probe the social spatialities that abortion laws construct. Empirically, the paper analyses trends in legislation to restrict medication abortion and two significant court challenges where abortion providers brought suit against medication abortion restrictions. Drawing on legislation and litigation over mifepristone, I demonstrate that restrictions on it function by anchoring mifepristone inside the clinical spaces and regulatory frameworks established for surgical abortion. In this way, mifepristone regulations circumscribe its availability in order to prevent the creation of alternative models for abortion provision that could re-arrange its geography and expand abortion access.